Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenetic Biosciences (XEN)

  Print      Mail a friend

Monday 13 February, 2012

Xenetic Biosciences

Phase I/IIa IV trial for ErepoXen?

RNS Number : 2607X
Xenetic Biosciences PLC
13 February 2012

13 February 2012

Xenetic Biosciences plc

('Xenetic' or 'the Company')

Xenetic commences Phase I/IIa IV trial for ErepoXen®


Xenetic Biosciences plc (LSE: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological and vaccines and novel cancer drugs, announces that, in a Phase I/IIa IV (intra venous) clinical trial, its co-development partner, the Serum Institute of India ("SIIL"), has dosed its first patient with their jointly-owned ErepoXen® candidate.


The 6-month trial is being conducted by India-based contract research organization SIRO Clinpharm Pvt. Ltd. SIRO is a leading full-service CRO with operations in India, the Middle East, Europe and the USA.  The trial will encompass 40 Chronic Renal Failure patients on dialysis and the end points will be to confirm safety and reductions in the frequency of dosage.  ErepoXen® is Xenetic's polysialyated erythropoietin (PSA-EPO) candidate for the treatment of patients with chronic anaemia.


EPO is a hormone produced by the kidneys that controls the production of red blood cells (RBCs). Because haemoglobin, found inside RBCs, normally carries oxygen from the lungs to the tissues, anemia leads to hypoxia (a lack of oxygen) in organs; since all human cells depend on oxygen for survival, this can have a wide range of clinical consequences. EPO is the hormone produced by the kidneys that stimulates the production of RBCs and so such therapy is the treatment of choice for affected patients.


In the case of End Stage Renal Disease (ESRD) patients, EPO is administered intravenously three times per week. Xenetic's ErepoXen has already demonstrated in Phase I and II(a) clinical trials based on the subcutaneous method of administration that it has the potential to be a long-acting version with a likely dosing profile of once per month.


The Phase II(a) clinical trials already completed successful by Serum Institute of India Ltd. were run on the subcutaneous method of administration method which accounts for around 20% of the global usage of EPO.  The new trial addresses the remaining 80% of the market and, upon completion, next stage Phase II(b) trials in India will be harmonised as to methods of administration, thereby compressing the timelines to complete the clinical trial process required prior to the market launch of the product. SIIL is also conducting repeated dosing toxicity studies which are designed to facilitate the early commencement of Phase III trials.


The global market for EPO drugs is estimated to be in the region of US $9billion. ErepoXen® is a performance-enhanced polysialyated form of EPO based on Xenetic's PolyXen enabling platform technology which, at its core uses Xenetic's all-natural PSA bio-polymer.  In earlier clinical trials ErepoXen has positively differentiated itself against its currently-marketed peers in terms of biodegradability, efficacy and is non-toxic, especially when compared to the PEGylated versions of currently marketed EPO drugs.  


Xenetic's PolyXen enabling platform is increasingly demonstrating attractive performance characteristics in the development of a number of bio-superior biologic drug candidates in the Company's current extensive product pipeline.


Commenting on the Phase I/IIa trial, M. Scott Maguire, CEO of Xenetic, said: "The commencement of our IV patient trials in India with ErepoXen® is an exciting step forward in combining the two methods of EPO administration.  We have previously announced positive Ph IIa subcutaneous results and now, with the intravenous trial, we cover the full $9B market potential of EPO. We now have four drug candidates under clinical development with our partners including two via our recent acquisition of SymbioTec in Germany. Our aim is to fund ErepoXen®through to an FDA Phase IIa at which point we will seek to out-license this candidate."



- Ends -



Xenetic Biosciences plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (NOMAD & Broker)

+44 (0)20 3205 7500

Claes Spång

Walbrook PR

+44 (0)20 7933 8780

Paul McManus

[email protected]

Paul Cornelius

[email protected]


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t